Emami Beheer

Beheer criteriumcontroles 3/4

De CEO Emami is Harsha Agarwal, benoemd in Apr2022, heeft een ambtstermijn van 2.58 jaar. De totale jaarlijkse vergoeding van { bedraagt ₹ 69.70M, bestaande uit 41.3% salaris en 58.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.13% van de aandelen van het bedrijf, ter waarde ₹ 393.20M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.6 jaar en 17.3 jaar.

Belangrijke informatie

Harsha Agarwal

Algemeen directeur

₹69.7m

Totale compensatie

Percentage CEO-salaris	41.3%
Dienstverband CEO	2.6yrs
Eigendom CEO	0.1%
Management gemiddelde ambtstermijn	2.6yrs
Gemiddelde ambtstermijn bestuur	17.3yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Harsha Agarwal's beloning veranderd ten opzichte van Emami's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	₹7b
Mar 31 2024	₹70m	₹29m	₹7b
Dec 31 2023	n/a	n/a	₹7b
Sep 30 2023	n/a	n/a	₹7b
Jun 30 2023	n/a	n/a	₹7b
Mar 31 2023	₹62m	₹26m	₹6b
Dec 31 2022	n/a	n/a	₹9b
Sep 30 2022	n/a	n/a	₹8b
Jun 30 2022	n/a	n/a	₹8b
Mar 31 2022	₹13m	₹12m	₹8b
Dec 31 2021	n/a	n/a	₹6b
Sep 30 2021	n/a	n/a	₹6b
Jun 30 2021	n/a	n/a	₹5b
Mar 31 2021	₹12m	₹11m	₹5b
Dec 31 2020	n/a	n/a	₹4b
Sep 30 2020	n/a	n/a	₹3b
Jun 30 2020	n/a	n/a	₹3b
Mar 31 2020	₹12m	₹11m	₹3b
Dec 31 2019	n/a	n/a	₹3b
Sep 30 2019	n/a	n/a	₹3b
Jun 30 2019	n/a	n/a	₹3b
Mar 31 2019	₹11m	₹10m	₹3b
Dec 31 2018	n/a	n/a	₹3b
Sep 30 2018	n/a	n/a	₹3b
Jun 30 2018	n/a	n/a	₹3b
Mar 31 2018	₹8m	₹7m	₹3b

Compensatie versus markt: De totale vergoeding ($USD 828.82K ) Harsha } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Indian markt ($USD 589.84K ).

Compensatie versus inkomsten: De vergoeding van Harsha is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Harsha Agarwal (48 yo)

2.6yrs

Tenure

₹69,696,000

Compensatie

Mr. Harsha Vardhan Agarwal, B.Com., serves as Vice Chairman and Managing Director of Emami Limited since April 01, 2022 and had been its Whole-Time Director since January 15, 2005 until April 01, 2022. He...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Radhe Goenka	Founder & Non-Executive Chairman	30.5yrs	₹1.03m	0.60% ₹ 1.9b
Harsha Agarwal	MD & Vice Chairman	2.6yrs	₹69.70m	0.13% ₹ 393.2m
Mohan Goenka	Vice Chairman & Whole Time Director	19.8yrs	₹69.70m	0.26% ₹ 826.0m
Radhe Agarwal	Founder & Chairman Emeritus	no data	₹400.00k	0.084% ₹ 263.9m
Naresh Bhansali	CEO of Finance	no data	₹29.72m	geen gegevens
Sandeep Sultania	Company Secretary & Compliance Officer and VP of Sales Commercial	1.5yrs	₹7.20m	geen gegevens
Sushil Goenka	Whole-Time Director	2.6yrs	₹41.26m	0.34% ₹ 1.1b
Prashant Goenka	Whole-Time Director	no data	₹34.87m	0.099% ₹ 310.7m
Priti Sureka	Whole Time Director	no data	₹34.87m	3.78% ₹ 11.8b
Sanjay Madan	President of Operations	no data	geen gegevens	geen gegevens
Rajesh Sharma	President of Finance & Investor Relations	no data	geen gegevens	geen gegevens
Shagun Tulsyan	President of Legal & Revenue	no data	geen gegevens	geen gegevens

2.6yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 531162 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Radhe Goenka	Founder & Non-Executive Chairman	30.5yrs	₹1.03m	0.60% ₹ 1.9b
Harsha Agarwal	MD & Vice Chairman	19.8yrs	₹69.70m	0.13% ₹ 393.2m
Mohan Goenka	Vice Chairman & Whole Time Director	19.8yrs	₹69.70m	0.26% ₹ 826.0m
Radhe Agarwal	Founder & Chairman Emeritus	30.5yrs	₹400.00k	0.084% ₹ 263.9m
Sushil Goenka	Whole-Time Director	29.5yrs	₹41.26m	0.34% ₹ 1.1b
Prashant Goenka	Whole-Time Director	10.8yrs	₹34.87m	0.099% ₹ 310.7m
Priti Sureka	Whole Time Director	14.8yrs	₹34.87m	3.78% ₹ 11.8b
Chandra Dhanuka	Non-Executive Independent Director	7.3yrs	₹1.52m	geen gegevens
Aditya Agarwal	Non-Executive Director	19.8yrs	₹730.00k	0.25% ₹ 778.2m
Debabrata Sarkar	Non-Executive Independent Director	5.8yrs	₹1.58m	geen gegevens
Mamta Binani	Independent Director	3.1yrs	₹1.10m	geen gegevens
Anand Rathi	Independent Director	2.3yrs	₹1.02m	geen gegevens

17.3yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 531162 zijn ervaren en ervaren (gemiddelde ambtstermijn van 17.3 jaar).

Emami Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Emami Limited, Annual General Meeting, Aug 27, 2024

Emami Limited Announces Change in Management

Emami Limited Announces Changes to the Senior Management Personnel

Insider recently bought ₹1.0m worth of stock

Emami Limited Announces Cessation of Mr. Vinod Rao, President-CCD, Personnel of Senior Management Effective from the Closing Hours of July 31, 2023

Emami Limited, Annual General Meeting, Aug 23, 2023

Recent updates

Emami Limited to Report Q2, 2025 Results on Nov 07, 2024

Emami Limited, Annual General Meeting, Aug 27, 2024

Price target increased by 8.3% to ₹777

First quarter 2025 earnings: EPS misses analyst expectations

Emami Limited to Report Q1, 2025 Results on Aug 01, 2024

Investor sentiment improves as stock rises 34%

Price target increased by 8.2% to ₹613

Full year 2024 earnings released: EPS: ₹16.55 (vs ₹14.50 in FY 2023)

Emami Limited (BSE:531162) signed a share purchase agreement to acquire 4.64% stake in Brillare Science Pvt. Ltd. from founder and other shareholders of Brillare Science Pvt. Ltd.

Dividend of ₹4.00 announced

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Emami Limited Approves Second Interim Dividend for the Financial Year 2023-24

Investor sentiment improves as stock rises 16%

Emami Limited Declares Interim Dividend for the Financial Year 2023-24

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Emami Limited (BSE:531162) completed the acquisition of 26% stake in Axiom Ayurveda Private Limited

Emami Limited (BSE:531162) entered into definitive agreement to acquire 26% stake in Axiom Ayurveda Private Limited.

Emami Limited Announces Change in Management

Manipal Health Enterprises Pvt Ltd acquired 84% stake in AMRI Hospitals Ltd. from Emami Limited (BSE:531162).

Manipal Health Enterprises Pvt Ltd acquired 84% stake in AMRI Hospitals Ltd. from Emami Limited (BSE:531162).

Emami Limited Announces Changes to the Senior Management Personnel

Insider recently bought ₹1.0m worth of stock

Emami May Seal AMRI Sale to Manipal Group This Month

Price target increased by 7.6% to ₹517

Emami Limited Announces Cessation of Mr. Vinod Rao, President-CCD, Personnel of Senior Management Effective from the Closing Hours of July 31, 2023

Full year 2023 earnings: EPS misses analyst expectations

Emami Limited to Report Q4, 2024 Results on May 30, 2024

Emami Limited Proposes Two Interim Dividends for the Financial Year 2022-23

Emami Limited, Annual General Meeting, Aug 23, 2023

Emami Limited to Report Q1, 2024 Results on Aug 07, 2023

Emami Limited Approves Executive Changes

Full year 2023 earnings: EPS misses analyst expectations

Price target decreased by 7.3% to ₹510

Third quarter 2023 earnings: EPS exceeds analyst expectations

Emami Limited Declares Second Interim Dividend for the Financial Year 2022-23

Emami Limited to Report Q3, 2023 Results on Feb 03, 2023

Max Healthcare Reportedly Eyeing AMRI Hospitals

Second quarter 2023 earnings: EPS exceeds analyst expectations

Second quarter 2023 earnings: EPS exceeds analyst expectations

Emami Limited Declares Interim Dividend for the Financial Year 2022-23

Emami Limited to Report Q2, 2023 Results on Nov 11, 2022

Emami Limited, Annual General Meeting, Sep 09, 2022

Consensus forecasts updated

First quarter 2023 earnings released: EPS: ₹1.67 (vs ₹1.75 in 1Q 2022)

Emami Limited (BSE:531162) acquired 30% stake in Cannis Lupus Services India Private Limited.

Emami Limited to Report Q1, 2023 Results on Jul 29, 2022

Full year 2022 earnings: EPS exceeds analyst expectations

Emami Limited Announces Executive Changes

Emami Limited (BSE:531162) acquired 19% equity stake in Tru Native F&B Private Limited.

Emami Limited (BSE:531162) announces an Equity Buyback for INR 1,620 million worth of its shares.

Emami Ltd Restructures Its Board, Effective April 1, 2022

Third quarter 2022 earnings: EPS exceeds analyst expectations

Emami Limited Announces Declaration of Second Interim Dividend

Second quarter 2022 earnings released: EPS ₹4.17 (vs ₹2.66 in 2Q 2021)

Upcoming dividend of ₹4.00 per share

Non-Executive Independent Director Rama Bijapurkar has left the company

First quarter 2022 earnings released: EPS ₹1.75 (vs ₹0.88 in 1Q 2021)

Price target increased to ₹619

Full year 2021 earnings released: EPS ₹10.23 (vs ₹6.67 in FY 2020)

New 90-day high: ₹502

Analysts increase EPS estimates to ₹9.78

Third quarter 2021 earnings released: EPS ₹4.70 (vs ₹3.18 in 3Q 2020)

Revenue and earnings beat expectations

Price target raised to ₹510

New 90-day high: ₹451

New 90-day high: ₹401

Emami Limited to Hit the Indian Market with Its Newest Offering ­Emasol-A Complete Range for Home Hygiene Products

Price target raised to ₹382

Emami Limited to Report Q2, 2021 Results on Nov 14, 2020

Emami Limited to Hit the Indian Market with Its Newest Offering Emasol-A Complete Range for Home Hygiene Products